This investment was made under a previous strategy. We disclose information on all our current investments, but narrative information on our pre-2012 investments, when we introduced a new strategy, may be limited.
Ming Hua (Gan & Lee) is a leading biotechnology company in China engaged in the development, manufacturing and commercialization of human therapeutics. Its top products are recombinant human insulin and insulin analogs.
Since 2012, we’ve only invested in Africa and South Asia. Investments outside these regions are from our pre-2012 portfolio.
- Rest of the World
We have seven priority sectors. However, we continue to invest outside these sectors, largely in the most challenging regions, as new investment supporting any sector helps to underpin the private sector, and create jobs and livelihoods for people.
- Investment type
We provide capital in three broad ways: direct equity, debt, and intermediated equity (principally through investment funds).
- Intermediated investment
- Qiming Venture Partners II LP
- Fund Manager:
- Qiming Venture Partners
- Start date
For direct investments, this is the date CDC committed capital to the business or project.
For funds, this is the date that CDC committed capital to the fund.
For underlying fund investments, this is the date that the fund invested capital into the business.e
- December 2009
This is the investee company’s place of incorporation; or a fund’s jurisdiction.